321 HARRISON AVENUE, BOSTON, MA
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Investor Presentation
Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Election of Directors - Thomas Civik, Freda Lewis-Hall, and Michael Metzger
Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership